2,5-二甲氧基-4-甲基安非他命 | 15588-95-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,5-二甲氧基-4-甲基安非他命
• 英文名称: 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane
• 英文别名: 1 (4 methyl 2,5 dimethoxyphenyl) 2 aminopropane；DOM；(−)2,5-dimethoxy-4-methylamphetamine；2,5-dimethoxy-4-methylamphetamine；(-)DOM；2,5-dimethoxy-4-methylphenylisopropylamine；1-(2,5-dimethoxy-4-methylphenyl)propan-2-amine
• CAS: 15588-95-1
• 化学式: C₁₂H₁₉NO₂
• 分子量: 209.288
• InChiKey: NTJQREUGJKIARY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

ADMET

代谢

为了更全面地描述精神拟态胺（1-(2,5-二甲氧基-4-甲基苯基)-2-氨基丙烷（DOM, STP）的代谢命运，研究了兔肝匀浆的10,000 X g上清液分数中母药可能形成的两种单酚和p-羟基醌代谢物。所有三种代谢物已经通过化学离子化质谱法，借助氘富集化合物进行了完全表征和定量估计。单-O-脱甲基反应的立体化学过程已经显示出S-氨基酚对映体的富集。讨论了关于母药作用方式和代谢O-脱甲基机制的机理含义。

In an effort to more fully characterize the metabolic fate of the psychotomimetic amine (1-(2, 5-dimethoxy-4-methylpheny)-2-aminopropane (DOM, STP), the formation of the two possible monophenols and the p-hydroquinone metabolites of the parent drug by 10,000 X g supernatent fractions of rabbit liver homogenates has been investigated. All three metabolites have been fully characterized and quantitatively estimated by chemical ionization mass spectrometry with the aid of deuterium enriched compounds. The stereochemical course of the mono-O-demethylation reactions has been shown to proceed with enantiomeric enrichment of the S-aminophenols. The mechanistic implications concerning the mode of action of the parent drug and metabolic O-demethylation are discussed.

来源:Hazardous Substances Data Bank (HSDB)

代谢

细胞色素P450酶系在药物代谢中扮演着重要角色。在人体中，CYP3A家族的酶负责大约50%的药物代谢过程。由于CYP3A酶的活性在个体之间以及同一个体不同组织中存在差异，因此，研究这些酶的基因多态性和表达调控对于理解药物代谢的个体差异和药物副作用具有重要意义。

The possible relationship between metabolism and psychotomimetic activity among the methoxylated 1-phenyl-2-aminopropanes led to our investigation of the in vitro O-demethylation of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (1, DOM, STP). Employing a sensitive and highly selective stable isotope dilution assay, we observed that rabbit liver homogenates biotransform the amine 1 to its 2-O-demethyl, 5-O-demethyl, and bis (O-demethyl) metabolite metabolites. Both monophenolic metabolites are enriched in their S enantiomers. The bis(O-demethyl) metabolite has structural, chemical, and electrochemical similarities to the sympatholytic agent "6-hydroxydopamine". The possible significance of metabolic O-demethylation in terms of the psychotomimetic properties of amine 1 is discussed.

来源:Hazardous Substances Data Bank (HSDB)

代谢

STP的代谢物已经在老鼠的尿液和粪便中被合成和鉴定。一种4-羟甲基化合物，由STP的4-甲基羟基化形成，占到了24小时尿液中分离出的代谢物总量的一半。4-羟甲基化合物的进一步氧化产物，即4-羧基代谢物和未改变的STP的比例为2比7。还检测到了一种微量的酮，它是由STP侧链的氧化产生的。在同一时间间隔的粪便中几乎只含有4-羧基代谢物，4-羟甲基代谢物和相对少量的未改变的STP，总共不到7%。在当前研究中，研究人员试图在大脑以及猴子大脑的区域性区域隔离STP的代谢物，以寻找代谢与行为效应之间的任何可能相关性。

Metabolites of STP have been synthesized and identified in rat urine and feces. A 4-hydroxymethyl compound which resulted from hydroxylation of the 4-methyl group of STP accounted for half of the total amount of the metabolites isolated in the 24 hour urine. The further oxidation product of the 4-hydroxymethyl compound, the 4-carboxy metabolite and unchanged STP were present in a ratio of 2 to 7. A trace amount of the ketone, derived from oxidation of the side-chain of STP, was also detected. The feces at the same time interval contained almost exclusively the 4-carboxy metabolite, with the 4-hydroxymethyl metabolite and a relatively small quantity of unchanged STP amounting to less than 7%. In the present study /investigators/ attempted to isolate metabolites of STP in monkey and rat brains, as well as in regional areas of the monkey brain for any possible correlation between metabolism and and the behavioral effects.

来源:Hazardous Substances Data Bank (HSDB)

代谢

致幻剂2,5-二甲氧基-4-甲基安非他命（DOM，STP）已知在各种物种中广泛代谢。当前研究表明，细胞色素P450 2D6是形成主要代谢物羟基DOM的唯一同工酶。此外，作者使用全扫描气相色谱-质谱（GC-MS）的系统性毒理分析（STA）程序适合于通过检测大鼠尿液中羟基DOM来证明摄入了常见药物使用者剂量的DOM。假设类似的代谢，所描述的STA程序应该适合于证明人类尿液中DOM的摄入。然而，DOM和其他代谢物，如去氨氧羟基DOM可能是CYP2D6差代谢者尿液中目标分析物。

The designer drug 2,5-dimethoxy-4-methyl-amphetamine (DOM, STP) is known to be extensively metabolized in various species. The current study showed that cytochrome P450 2D6 was the only isoenzyme involved in formation of the main metabolite hydroxy DOM. In addition, the authors' systematic toxicological analysis (STA) procedure using full-scan GC-MS was suitable to prove an intake of a common drug users' dose of DOM by detection of hydroxy DOM in rat urine. Assuming similar metabolism, the described STA procedure should be suitable for proof of an intake of DOM in human urine. However, DOM and/or other metabolites such as deamino-oxo-hydroxy DOM might be the target analyte in urine of CYP2D6 poor metabolizers.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

立即急救：确保已经进行了充分的中毒物清洗。如果患者停止呼吸，开始人工呼吸，最好使用需求阀复苏器、袋阀面罩装置或口袋面罩，按训练操作。如有必要，进行心肺复苏。立即用缓慢流动的水冲洗受污染的眼睛。不要催吐。如果发生呕吐，让患者前倾或置于左侧（如果可能，头部向下）以保持呼吸道畅通，防止吸入性肺炎。保持患者安静，维持正常体温。寻求医疗帮助。/毒物A和B/

Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

基本治疗：建立专利气道（如需要，使用口咽或鼻咽气道）。如有必要，进行吸痰。观察呼吸不足的迹象，如有需要，协助通气。通过非循环呼吸面罩以10至15升/分钟的速度给予氧气。监测肺水肿，如有必要，进行治疗……。监测休克，如有必要，进行治疗……。预防癫痫发作，如有必要，进行治疗……。对于眼睛污染，立即用水冲洗眼睛。在运输过程中，用0.9%的生理盐水（NS）连续冲洗每只眼睛……。不要使用催吐剂。对于摄入，如果患者能吞咽、有强烈的呕吐反射且不流口水，则用水冲洗口腔，并给予5毫升/千克，最多200毫升的水进行稀释……。在去污后，用干性无菌敷料覆盖皮肤烧伤……。/毒物A和B/

Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

高级治疗：对于昏迷、严重肺水肿或严重呼吸困难的病人，考虑进行口咽或鼻咽气管插管以控制气道。使用气囊面罩装置的正压通气技术可能有益。考虑对肺水肿进行药物治疗...。对于严重的支气管痉挛，考虑使用β受体激动剂，如沙丁胺醇（舒喘灵）...。监测心率和必要时治疗心律失常...。开始静脉输注D5W/SRP：“保持开放”，最小流量/。如果出现低血容量的迹象，使用0.9%的生理盐水（NS）或乳酸钠林格氏液。对于伴有低血容量迹象的低血压，谨慎给予液体。注意液体过载的迹象...。使用地西泮或劳拉西泮治疗癫痫...。使用丙美卡因氢氯化物协助眼部冲洗...。/毒物A和B/

Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

保持呼吸道通畅，必要时协助通气。如果出现激动、惊厥、昏迷和高热，则进行治疗。对于治疗激动，苯二氮卓类药物通常有效，尽管也可以使用丁酰苯类药物。持续监测体温、其他生命体征和心电图至少6小时。没有特定的解毒剂。高血压最好通过镇静治疗，如果无效，可以使用如酚妥拉明或硝普钠等静脉血管扩张剂。用普萘洛尔或艾司洛尔治疗心动过速。... 去污：如果条件适当，口服活性炭。在小到中等剂量摄入后，如果可以及时给予活性炭，则不需要进行胃灌洗。在摄入含有药物的包装（"身体填充物"）后，考虑全肠灌洗和重复给予活性炭。增强消除：透析和血液灌注无效。重复剂量的活性炭尚未进行研究。... /苯丙胺类/

Maintain an open airway and assist ventilation if necessary. Treat agitation, seizures, coma, and hyperthermia if they occur. Benzodiazepines are usually satisfactory for treatment of agitation, although butyrophenones may also be used. Continuously monitor the temperature, other vital signs, and ECG for a minimum of 6 hours. There is no specific antidote. Hypertension is best treated by sedation and, if this is not effective, a parenteral vasodilator such as phentolamine or nitroprusside. Treat tachycardia with propranolol or esmolol. ... Decontamination: administer activated charcoal orally if conditions are appropriate. Gastric lavage is not necessary after small to moderate ingestions if activated charcoal can be given promptly. Consider whole-bowel irrigation and repeat doses of charcoal after ingestion of drug filled packets ("body stuffers"). Enhanced elimination: Dialysis and hemoperfusion are not effective. Repeat-dose charcoal has not been studied. ... /Amphetamines/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 人类毒性摘录

/其他毒性信息/ DOM /(4-甲基-2,5-二甲氧基苯丙胺)/ ... 特别有趣，因为在低剂量下/它/产生轻度的欣快感和增强的自我意识，而没有感知扭曲或致幻效果。在高剂量下，DOM具有典型的迷幻作用。

/OTHER TOXICITY INFORMATION/ DOM /(4-methyl-2,5-dimethoxyamphetamine)/ ... is particularly interesting because at low doses /it/ produces mild euphoria and enhanced self-awearness without perceptual distortion or hallucinogenic effects. At higher doses DOM has typical psychedelic activity.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

DOM（2,5-二甲氧基-4-甲基安非他明）在摄入2到14毫克的剂量后1到2小时内产生效果。摄入剂量的20%在24小时内以未改变的形式出现在尿液中。

DOM produces effects within 1 to 2 hours of ingestion of doses ranging from 2 to 14 mg. Twenty percent of an ingested dose appears unchanged in the urine within 24 hours.

来源:Hazardous Substances Data Bank (HSDB)

反应信息

• 作为反应物：
  描述：

  2,5-二甲氧基-4-甲基安非他命 反应 2.0h， 生成 (-)-DOM
  参考文献：
  名称：

  拟精神病的苯基烷基胺的结构活性关系。

  摘要：

  DOI：

  10.1021/jm00256a016
• 作为产物：
  描述：

  2,5-二甲氧基-4-甲苯甲醛 在 palladium on activated charcoal 盐酸 、 ammonium acetate 、 氢气 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 生成 2,5-二甲氧基-4-甲基安非他命
  参考文献：
  名称：

  致幻剂 1-(2,5-二甲氧基-4-甲基苯基)-2-氨基丙烷 (DOM) 四种可能的体外代谢物的合成

  摘要：

  描述了致幻剂 1-(2,5-二甲氧基-4-甲基苯基)-2-氨基丙烷 (DOM) 的四种可能体外代谢物的合成。这些化合物、1-(2,5-二甲氧基-4-甲基苯基(-2-丙酮、相应的肟、1-(2,5-二甲氧基-4-甲基苯基)-2-丙醇和1-(2,5 -二甲氧基)-4-甲基苯基-2-(羟氨基)丙烷，可能是DOM侧链代谢氧化的产物。

  DOI：

  10.1139/v74-063

文献信息

• D-AMINO ACID OXIDASE INHIBITORS AND THERAPEUTIC USES THEREOF
  申请人：Tsai Guochuan Emil

  公开号：US20190112289A1

  公开（公告）日：2019-04-18

  The present invention relates to compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: each of A, B, C, D, and E, independently, is C, N, N—H, O, S, or absent is a single bond or a double bond; each of X, Y, and Z, independently, is aryl, heteroaryl, aralkyl, H, or absent; each of L 1 and L 2 , independently, is a moiety selected from O, CH 2 , C═O, C 2-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, —((CH 2 ) n —W)—, wherein n=0, 1, 2, 3, 4, or 5, and W is O or S, or absent; and when L 2 is absent, Z is aryl or heteroaryl fused with B C. Also provided in the present invention is a method for inhibiting, treating and/or reducing the risk of a neuropsychiatric disorder, comprising administering a subject in need a composition comprising a compound of Formula (I).

  本发明涉及以下式（I）的化合物： 或其药学上可接受的盐，其中：A、B、C、D 和 E 中的每一个独立地是 C、N、N—H、O、S 或不存在 是单键或双键；X、Y 和 Z 中的每一个独立地是芳基、杂环芳基、芳基烷基、H 或不存在；L 1 和 L 2 中的每一个独立地是从 O、CH 2 、C═O、C 2-10 烷基、C 2-10 烯基、C 2-10 炔基、—((CH 2 ) n —W)— 中选择的基团，其中 n=0、1、2、3、4 或 5，W 是 O 或 S，或不存在；当 L 2 不存在时，Z 是与 B 相融合的芳基或杂环芳基。本发明还提供了一种用于抑制、治疗和/或减少神经精神障碍风险的方法，包括向需要的受试者施用包含式（I）化合物的组合物。
• [EN] 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE<br/>[FR] AGONISTES DE RÉCEPTEUR 5-HT2C ET COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：ARENA PHARM INC

  公开号：WO2017023679A1

  公开（公告）日：2017-02-09

  Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.

  在某些实施例中提供了一些符合本文所定义的A式化合物，其调节5-HT2C受体的活性。在某些实施例中还提供了一些方法，例如用于体重管理、诱导饱腹感、减少食物摄入，以及预防和治疗肥胖、抗精神病药物引起的体重增加、2型糖尿病、普拉德-威利综合征、烟草/尼古丁依赖、药物成瘾、酒精成瘾、病理性赌博、奖赏缺乏综合征和性成瘾，强迫症谱系障碍和冲动控制障碍（包括咬指甲和咬甲症），睡眠障碍（包括失眠、睡眠结构碎裂和慢波睡眠紊乱），尿失禁，精神障碍（包括精神分裂症、厌食症和暴食症），阿尔茨海默病，性功能障碍，勃起功能障碍，癫痫，运动障碍（包括帕金森病和抗精神病药物引起的运动障碍），高血压，血脂异常，非酒精性脂肪肝病，肥胖相关肾脏疾病和睡眠呼吸暂停症。
• D-AMPHETAMINE COMPOUNDS, COMPOSITIONS, AND PROCESSES FOR MAKING AND USING THE SAME
  申请人：KemPharm, Inc.

  公开号：US20200131130A1

  公开（公告）日：2020-04-30

  Disclosed are d-amphetamine compounds and compositions comprising at least one organic acid covalently bound to d-amphetamine, a salt thereof, a derivative thereof, or a combination thereof. Methods of making and using the same are also disclosed.

  揭示了d-安非他明化合物和组合物，其中至少有一种有机酸以共价键结合到d-安非他明，其盐，衍生物或其组合物。还公开了制备和使用这些化合物的方法。
• AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS
  申请人：CHEMAPOTHECA, LLC

  公开号：US20180243241A1

  公开（公告）日：2018-08-30

  The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

  这项发明还涉及包含高纯度苯丙胺和苯丙胺类化合物的药物组合物，这些化合物是通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成而得到的，并且涉及通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成而得到的苯丙胺化合物的制造、输送和使用方法。
• [EN] 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE<br/>[FR] AGONISTES DU RÉCEPTEUR 5-HT2C ET COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：ARENA PHARM INC

  公开号：WO2015066344A1

  公开（公告）日：2015-05-07

  Provided are 5-HT2C receptor agonists. Also provided are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided are compositions comprising a selective 5-HT2C receptor agonist, optionally in combination with a supplemental agent, and methods for reducing the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aiding in the cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a tobacco product; aiding in smoking cessation and preventing associated weight gain; controlling weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; reducing weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; treating nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or withdrawal; or reducing the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use comprising administering a selective 5-HT2C receptor agonist, optionally in combination with a supplemental agent.

  提供了5-HT2C受体激动剂。还提供了用于体重管理、诱导饱腹感、减少食物摄入量、预防和治疗肥胖、抗精神病药物引起的体重增加、2型糖尿病、普拉德-威利综合征、烟草/尼古丁依赖、药物成瘾、酒精成瘾、病态赌博、奖赏缺乏综合征和性成瘾）、强迫症谱系障碍和冲动控制障碍（包括咬指甲和咬甲）、睡眠障碍（包括失眠、睡眠结构碎裂和慢波睡眠紊乱）、尿失禁、精神障碍（包括精神分裂症、厌食症和暴食症）、阿尔茨海默病、性功能障碍、勃起功能障碍、癫痫、运动障碍（包括帕金森病和抗精神病药物引起的运动障碍）、高血压、血脂异常、非酒精性脂肪肝病、肥胖相关肾脏疾病和睡眠呼吸暂停。还提供了包含选择性5-HT2C受体激动剂的组合物，可选地与辅助剂结合，以及用于减少个体尝试减少吸烟频率的吸烟频率；帮助个体戒除或减少使用烟草制品的个体戒除或减少使用烟草制品；帮助戒烟并预防相关体重增加；通过个体尝试戒烟来控制与戒烟相关的体重增加；通过个体尝试戒烟来减少与戒烟相关的体重增加；治疗尼古丁依赖、成瘾和/或戒断的个体尝试治疗尼古丁依赖、成瘾和/或戒断；或减少个体尝试戒除尼古丁使用的复发可能性，包括给予选择性5-HT2C受体激动剂，可选地与辅助剂结合。

表征谱图